Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program

Pediatric Blood and Cancer

Volumn 53, Issue 4, 2009, Pages 594-598

  Gorlick, Richard ^a,i   Kolb, E Anders ^b   Houghton, Peter J ^c   Morton, Christopher L ^c   Phelps, Doris ^c   Schaiquevich, Paula ^c   Stewart, Clinton ^c   Keir, Stephen T ^d   Lock, Richard ^e   Carol, Hernan ^e   Reynolds, C Patrick ^f   Maris, John M ^g   Wu, Jianrong ^c   Smith, Malcolm A ^h  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^f TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h NATIONAL CANCER INSTITUTE   (United States)

ⁱ Hematology Oncology ^*  (United States)

Author keywords

Developmental therapeutics; Lapatinib; Preclinical testing

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG TOLERABILITY; EWING SARCOMA; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MEDULLOBLASTOMA; MOUSE; NEPHROBLASTOMA; NEUROBLASTOMA; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; RHABDOID TUMOR; SOLID TUMOR; WESTERN BLOTTING; XENOGRAFT; ANIMAL; DRUG ANTAGONISM; DRUG SCREENING; PROTO ONCOGENE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENES, ERBB-2; HUMANS; MICE; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 69849094782     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21989     Document Type: Article

References (24)

1. Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene 2000;19:5548-5557.
2. Dancey JE. Epidermal growth factor receptor inhibitors in non-small cell lung cancer. Drugs 2007;67:1125-1138. (Pubitemid 46871023)
3. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712. (Pubitemid 19147683)
4. Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001;1:85-94.
5. Rusnak DW, Alligood KJ, Mullin RJ, et al. Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines. Cell Prolif 2007;40:580-594.
6. Xia W, Mullin RJ, Keith BR, et al. Anti-tumor activity of G W572016: A dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002;21:6255-6263.
7. Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006;66:1630-1639. (Pubitemid 43259947)
8. Frgala T, Kalous O, Proffitt RT, et al. A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations. Mol Cancer Ther 2007;6:886-897. (Pubitemid 46554558)
9. Houghton PJ, Morton CL, Kolb EA, et al. Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer 2008;50:37-45. (Pubitemid 350234263)
10. Friedman HS, Colvin OM, Skapek SX, et al. Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res 1988;48:4189-4195.
11. Graham C, Tucker C, Creech J, et al. Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo. Clin Cancer Res 2006;12:223-234. (Pubitemid 43166198)
12. Peterson JK, Tucker C, Favours E, et al. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models. Clin Cancer Res 2005;11:6950-6958.
13. Liem NL, Papa RA, Milross CG, et al. Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood 2004;103:3905-3914.
14. Houghton PJ, Morton CL, Tucker C, et al. The pediatric preclinical testing program: Description of models and early testing results. Pediatr Blood Cancer 2007;49:928-940. (Pubitemid 350022448)
15. D'Argenio D, Schumitzky A. ADAPT II User's Guide. Los Angeles: USC, Biomedical Simulations Resource; 1990.
16. Kurmasheva RT, Harwood FC, Houghton PJ. Differential regulation of vascular endothelial growth factor by Akt and mammalian target of rapamycin inhibitors in cell lines derived from childhood solid tumors. Mol Cancer Ther 2007;6:1620-1628.
17. Fouladi M, Blaney SM, Onar T, et al. A phase I trial of lapatinib in children with refractory CNS malignancies: A Pediatric Brain Tumor Consortium Study. Proc Int Symp Pediatr Neuro-Oncol 2008.
18. Hughes DP, Thomas DG, Giordano TJ, et al. Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res 2004;64:2047-2053.
19. Tamura S, Hosoi H, Kuwahara Y, et al. Induction of apoptosis by an inhibitor of EGFR in neuroblastoma cells. Biochem Biophys Res Commun 2007;358:226-232. (Pubitemid 46719107)
20. Bredel M, Pollack IF, Hamilton RL, et al. Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood. Clin Cancer Res 1999;5:1786-1792. (Pubitemid 29334460)
21. Gilbertson RJ, Bentley L, Hernan R, et al. ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease. Clin Cancer Res 2002;8:3054-3064. (Pubitemid 35155014)
22. Gilbertson RJ. ERBB2 in pediatric cancer: Innocent until proven guilty. Oncologist 2005;10:508-517. (Pubitemid 41266332)
23. Gorlick R, Huvos AG, Heller G, et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 1999;17:2781-2788. (Pubitemid 29415235)
24. Akatsuka T, Wada T, Kokai Y, et al. ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer 2002;94:1397-1404. (Pubitemid 34212632)